Australia markets closed

23andMe Holding Co. (ME)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4235+0.0058 (+1.39%)
At close: 04:00PM EDT
0.4240 +0.00 (+0.12%)
After hours: 07:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4177
Open0.4154
Bid0.4203 x 1800
Ask0.5430 x 200
Day's range0.4150 - 0.4269
52-week range0.3500 - 2.0300
Volume3,058,601
Avg. volume5,349,285
Market cap207.624M
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    23andMe Launches New Genetic Report on Bipolar Disorder

    Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variantsSOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the co

  • GlobeNewswire

    23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

    Study aims to fill research gap and empower people through access to information about their healthSUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic In

  • GlobeNewswire

    23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

    – 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed Q3W – Tumor CD200 is emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a